I-Mab
Anti-CD73 anti-PD-L1 bispecific antibodies
Last updated:
Abstract:
Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.
Status:
Grant
Type:
Utility
Filling date:
25 Jul 2019
Issue date:
15 Jun 2021